EnteroBiotix raises over USD21m in Series A financing
EnteroBiotix, a biopharmaceutical company developing high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, has held the final closing of its oversubscribed USD21.5 million (GBP15.5 million) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development